Patients at the Myeloma Center have access to the newest therapies for plasma cell disorders through enrollment onto clinical trials. New clinical trials are now under continuing enrollment under the care of your treating physician. The myeloma center has access to both pharmaceutical industry and physician investigator initiated clinical trials as part of a world-class clinical research program.
In addition to clinical research, Weill Cornell Medical College has an active basic science laboratory-based research program in myeloma where new targets for drug therapy and disease control can be discovered. Innovations in the laboratory can then be used in an active bench-to-clinic translational research context, this offering patients in need the latest in personalized drug therapies.
Myeloma is a cancer of a type of white blood cell called the plasma cell. It is the job of the plasma cell to produce immunoglobulins, proteins which serve in an integral role in immune system protection. An abnormal proliferation of one type (or clone) or plasma cell can lead to a spectrum of blood disorders including MGUS (monoclonal gammopathy of undetermined significance), multiple myeloma, amyloidosis, light chain deposition disease, amongst others.
Myeloma Research Updates at the 2017 American Society of Hematology Annual Meeting
Researchers and physicians at the Weill Cornell Medicine and NewYork-Presbyterian Multiple Myeloma Center presented cutting-edge research at this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, an educational gathering of over 25,000 clinicians and scientists from around the world who are working to conquer blood disease.
Lymphoma and Myeloma 2017:
An International Congress on Hematologic Malignancies
Approximately 1,000 hematologists, oncologists, and other healthcare professionals from across the globe came together for the annual Lymphoma and Myeloma Congress in New York City from October 26 – 28, 2017.
Nurse Practitioner at Myeloma Center Named Oncology Nurse of the Year
Karen Pekle, nurse practitioner at the Weill Cornell Medicine and NewYork-Presbyterian Myeloma Center, was awarded the 2017 Oncology Nurse of the Year Award by the Hotel Keys of Hope Program – a joint initiative between Extended Stay America and the American Cancer Society.
16th International Myeloma Workshop
Dr. Ruben Niesvizky, Director at the Weill Cornell Myeloma Center, was invited to speak at the 16th International Myeloma Workshop to present on promising agents for patients with relapsed or refractory myeloma that are currently in phase II clinical trials.
The Myeloma Center is Teaming Up with the Leukemia & Lymphoma Society to Light the Night
We are proud to be supporting the 2016 Leukemia & Lymphoma Society (LLS) Light the Night Event! Because of the commitment of organizations like LLS to fund innovative research projects and connect patients with supportive services, we have made great progress in the fight against multiple myeloma. Learn more about our research and join our team!